Leading US University Includes DiviTum® in a New Study of Breast Cancer with Ibrance
Johns Hopkins University, Maryland, USA includes DiviTum® in a new study of metastatic breast cancer to study the development of resistance and efficacy of the new drug Ibrance® (palbociclib, Pfizer).
100 women with metastasized breast cancer will be included in the study, with the objective to find markers to identify early development of resistance of today's standard treatment in combination with Ibrance®. By early identification of women who are not responding to treatment, these patients can be offered other therapies and the opportunity for more effective treatment and better outcome. DiviTum® is used to analyze tumor growth rate and treatment efficacy by analysing blood samples from patients before and during therapy. About 450,000 women live with the disease in Europe and the United States. 80% of these patients have hormone-positive breast cancer, which is the type of cancer studied in the current study.
Johns Hopkins University's School of Medicine is one of the United States leading universities and cancer institutes. Johns Hopkins Hospital opened in 1889 and has been ranked No. 1 in the United States by U.S. News & World Report in 22 of 27 years. More than 20 Nobel Prize winners derive from Johns Hopkins, which are also the leading university in US in terms of investment in research and development.
"We are pleased that more people see the value of DiviTum® and that we can collaborate with additional, high profile US universities. With DiviTum® we want to provide a tool that faster than current methods can answer if the treatment is effective and beneficial to the patient. The study at Johns Hopkins University is especially valuable as DiviTum® will be used to quickly evaluate the effects of today's standard treatments combined with Ibrance for a large patient group." says Anders Rylander, CEO Biovica.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
This cookie is installed by Google Analytics.
A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
Hotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
Hotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
Hotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.